LifeMD is expected to report Q2 2026 revenue of $49.16 million and a consensus loss per share of $0.15, while its current stock price of $3.84 trades well below the average analyst target of $9.88. Investors are primarily focused on the growth trajectory of the company’s Weight Management program and whether LifeMD can meet its guidance to return to Adjusted EBITDA profitability this quarter.
The company is navigating its first full year as a telehealth pure-play following the divestiture of its WorkSimpli subsidiary, a move that shifted focus toward higher-margin medical services. Despite a year-over-year revenue decline due to the divestiture, subscriber momentum in GLP-1 treatments remains strong, with management targeting an annualized revenue run rate of $250 million by year-end.